Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Gray Sheet

Executive Summary

Firm initiates randomized, 200-patient, multi-center Phase III pivotal study at one site with two sites to follow shortly for the Intercept red blood cell system using Helinx pathogen inactivation technology developed by Cerus. The primary endpoint of the trial will compare Intercept processed red blood cells to red blood cells not prepared with a pathogen inactivation process. A second 50-patient pivotal study to follow "shortly" will compare Intercept cells to control red blood cells in support of patients with chronic anemia due to hereditary disorders such as sickle cell disease...



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts